Misplaced Pages

Co-amilozide (BAN) is a non-proprietary combination of amiloride and hydrochlorothiazide. Co-amilozide is used in the treatment of hypertension and congestive heart failure with the tendency of the thiazide to cause low potassium levels (hypokalaemia) offset by the potassium-sparing effects of amiloride.

Formulation

Two strengths of co-amilozide are currently available in the UK:

• 2.5 mg amiloride and 25 mg hydrochlorothiazide, BAN of Co-amilozide 2.5/25 (brand name Moduret 25)
• 5 mg amiloride and 50 mg hydrochlorothiazide, BAN of Co-amilozide 5/50 (brand name Moduretic)

In North America:

• Moduretic (U.S., Canada)
  • Moduretic 5-50 (U.S., Canada)
• Novamilor (Canada)

Side effects

The most common side effect is headache (about 8% of people taking it) and nausea, loss of appetite, weakness, rash and dizziness (each about 3%).

Common side effects (1/10 - 1/100) include:

• General: weakness, fatigue, loss of appetite, headache, dizziness.
• Circulatory system: arrhythmia.
• Gastrointestinal: nausea, diarrhea, abdominal pain.
• Skin: exanthema, itching.
• Respiratory system: shortness of breath, cough.
• Metabolic: elevated blood sugar in diabetic patients, elevated uric acid levels in the blood.
• Musculoskeletal: pain in the limbs.

References

1. British National Formulary 54 September 2007
2. ^ the Swedish official drug catalog > Normorix Retrieved on Mars 30, 2010

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Potassium-sparing diuretics
• Thiazides
• Combination drugs
• Cardiovascular system drug stubs